

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:


**Listing of Claims:**

Claims 1-16 (canceled)


**Claim 17 (currently amended):** A compound of formula 1:



wherein  $\text{Ar}^1$  is



wherein  $\text{R}^{12}$  is selected from the group consisting of



$\text{R}^{13}$  represents Cl, Br,  $\text{COO}(\text{C}_{1-4})\text{alkyl}$  and  
 if  $\text{R}^9$  is  $\text{NO}_2$ , Cl or Br, then  $\text{R}^{13}$  may also represent F or  $\text{CH}_3$ ;


$R^{14}$ ,  $R^{15}$ ,

$R^{31}$ ,  $R^{32}$ ,


$R^{33}$  are each independently selected from the group consisting of H, (C<sub>1-6</sub>)alkyl, (C<sub>3-7</sub>)cycloalkyl, (C<sub>3-7</sub>)cycloalkyl-(C<sub>1-3</sub>)alkyl, (C<sub>2-6</sub>)alkenyl, O-(C<sub>1-4</sub>)alkyl, S-(C<sub>1-4</sub>)alkyl, halo, CF<sub>3</sub>, OCF<sub>3</sub>, OH, NO<sub>2</sub>, CN, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>-(C<sub>1-4</sub>)alkyl, C(O)OR<sup>1</sup> wherein  $R^1$  is H or (C<sub>1-4</sub>)alkyl, or NR<sup>2</sup>R<sup>3</sup> wherein  $R^2$  and  $R^3$  each independently is H or (C<sub>1-4</sub>)alkyl;

$R^{30}$  represents H, Cl, Br, COO(C<sub>1-4</sub>)alkyl;

$R^{12C}$ —is a phenyl of formula



wherein  $R^{13C}$ ,  $R^{14C}$  and  $R^{15C}$  each independently represents H, (C<sub>1-6</sub>)alkyl, (C<sub>3-7</sub>)cycloalkyl, (C<sub>3-7</sub>)cycloalkyl-(C<sub>1-3</sub>)alkyl, (C<sub>2-6</sub>)alkenyl, O-(C<sub>1-4</sub>)alkyl, S-(C<sub>1-4</sub>)alkyl, halo, CF<sub>3</sub>, OCF<sub>3</sub>, OH, NO<sub>2</sub>, CN, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>-(C<sub>1-4</sub>)alkyl, C(O)OR<sup>4</sup> wherein  $R^4$  is H or (C<sub>1-4</sub>)alkyl, or NR<sup>2</sup>R<sup>3</sup> wherein  $R^2$  and  $R^3$  each independently is H or (C<sub>1-4</sub>)alkyl; provided that at least one of  $R^{13C}$ ,  $R^{14C}$  and  $R^{15C}$  is other than hydrogen; or  $R^{12C}$  is




wherein  $R^{30}$ ,  $R^{31}$ ,  $R^{32}$ ,  $R^{33}$  are as defined hereinbefore; and

$R^{20A}$ —is H, (C<sub>1-4</sub>)alkyl, (C<sub>3-7</sub>)cycloalkyl or (C<sub>3-7</sub>)cycloalkyl-(C<sub>1-3</sub>)alkyl, wherein said alkyl, cycloalkyl or cycloalkylalkyl may be monosubstituted with OH; and

X is S or O;

W is CH<sub>2</sub>C(O)NR<sup>6</sup> wherein  $R^6$  is H or (C<sub>1-4</sub>)alkyl; and


Ar<sup>2</sup> is selected from the group consisting of




wherein  $\mathbf{R}^9$  is halo or  $\text{NO}_2$ ; and if  $\mathbf{R}^{13}$  is Cl or Br, then  $\mathbf{R}^9$  may also represent  $(\text{C}_{1-3})\text{alkyl}$ ;  $\mathbf{R}^{10}$ ,  $\mathbf{R}^{11}$  are independently of each other selected from the group consisting of H,  $(\text{C}_{1-6})\text{alkyl}$ ,  $(\text{C}_{3-7})\text{Cycloalkyl}$ ,  $(\text{C}_{3-7})\text{Cycloalkyl}-(\text{C}_{1-3})\text{alkyl}$ ,  $(\text{C}_{2-6})\text{alkenyl}$ ,  $\text{O}(\text{C}_{1-6})\text{alkyl}$ ,  $\text{S}(\text{C}_{1-6})\text{alkyl}$ , halo,  $\text{CF}_3$ ,  $\text{OCF}_3$ , OH,  $\text{NO}_2$ , CN,  $-\text{NR}^{\text{N}1}\text{R}^{\text{N}2}$ ,  $-\text{C}(\text{O})\text{R}^{21}$ ,  $-(\text{C}_{1-3})\text{alkyl}-\text{C}(\text{O})\text{R}^{21}$ ,  $-\text{C}(\text{O})\text{OR}^{22}$ ,  $-(\text{C}_{1-3})\text{alkyl}-\text{C}(\text{O})\text{OR}^{22}$ ,  $-\text{SO}_2-(\text{C}_{1-3})\text{alkyl}-\text{C}(\text{O})\text{OR}^{22}$ , wherein  $\mathbf{R}^{21}$  is  $(\text{C}_{1-4})\text{alkyl}$  and  $\mathbf{R}^{22}$  is H or  $(\text{C}_{1-4})\text{alkyl}$ ;  $-(\text{C}_{1-3})\text{alkyl}-\text{C}(\text{O})\text{NH}_2$ ,  $\text{C}(\text{O})\text{NH}_2$ ,  $\text{S}(\text{O})-(\text{C}_{1-6})\text{alkyl}$ ,  $-\text{SO}_2-(\text{C}_{1-6})\text{alkyl}$ ,  $-\text{SO}_2\text{-phenyl}$ ,  $-\text{SO}_2\text{-NH}_2$ , phenyl, phenylmethyl, 2-, 3- or 4-pyridinyl, 1-pyrrolyl, whereby said phenyl, pyridinyl and pyrrolyl may have one or more substituents selected from the group consisting of halo,  $\text{NO}_2$ ,  $\text{C}_{1-3}\text{-alkyl}$  and  $\text{CF}_3$ ;  
wherein  $\mathbf{R}^{\text{N}1}$ ,  $\mathbf{R}^{\text{N}2}$  each independently represent H or  $(\text{C}_{1-6})\text{alkyl}$ , whereby  $\mathbf{R}^{\text{N}1}$  and  $\mathbf{R}^{\text{N}2}$  may be covalently bonded to each other to form together with the N-atom to which they are attached to a 4 to 7-membered heterocycle whereby the  $-\text{CH}_2-$  group at the position 4 of a 6 or 7-membered heterocycle may be replaced by  $-\text{O}-$ ,  $-\text{S}-$  or  $-\text{NR}^{\text{N}3}-$  wherein  $\mathbf{R}^{\text{N}3}$  represents H,  $-\text{C}(\text{O})\text{OR}^{22}$ ,  $(\text{C}_{1-6})\text{alkyl}$ ,  $(\text{C}_{3-7})\text{cycloalkyl}$  or  $(\text{C}_{3-7})\text{cycloalkyl}-(\text{C}_{1-3})\text{alkyl}$ , wherein  $\mathbf{R}^{22}$  is H or  $(\text{C}_{1-4})\text{alkyl}$ ;

or a pharmaceutically acceptable salt thereof.

**Claim 18 (currently amended):** The compound of formula 1 according to claim 17 wherein  $\mathbf{Ar}^1$  is



wherein  $\mathbf{R}^{12}$  is selected from the group consisting of



wherein  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{20A}$ ,  $R^{30}$ ,  $R^{31}$ ,  $R^{32}$  and  $R^{33}$  are as defined in claim 17.

**Claim 19 (original):** The compound of formula 1 according to claim 18 wherein

$R^{13}$  represents Cl or Br and

if  $R^9$  is  $NO_2$ , Cl or Br, then  $R^{13}$  may also represent F or  $CH_3$ ;


$R^{14}$ ,  $R^{15}$ ,

$R^{31}$ ,  $R^{32}$ ,


$R^{33}$  are each independently selected from the group consisting of H,  $(C_{1-6})$ alkyl,  $(C_{3-7})$ cycloalkyl,  $(C_{3-7})$ cycloalkyl- $(C_{1-3})$ alkyl,  $(C_{2-6})$ alkenyl, O- $(C_{1-4})$ alkyl, S- $(C_{1-4})$ alkyl, halo,  $CF_3$ ,  $OCF_3$ , OH,  $NO_2$ , CN,  $SO_2NH_2$ ,  $SO_2-(C_{1-4})$ alkyl,  $C(O)OR^1$  wherein  $R^1$  is H or  $(C_{1-4})$ alkyl, or  $NR^2R^3$  wherein  $R^2$  and  $R^3$  each independently is H or  $(C_{1-4})$ alkyl; and  $R^{30}$  represents Cl or Br.


**Claim 20 (original):** The compound of formula 1 according to claim 19 wherein **W** is  $CH_2C(O)NH$ .

**Claim 21 (original):** A compound according to claim 17 wherein



wherein  $R^{12}$  is selected from the group consisting of






$\text{X}$  is S;


$\text{W}$  is  $\text{CH}_2\text{C}(\text{O})\text{NR}^6$  wherein  $\text{R}^6$  is H or  $(\text{C}_{1-4})$ alkyl; and

$\text{Ar}^2$  is




wherein  $\text{R}^9$  is halo or  $\text{NO}_2$ ; or

$\text{Ar}^2$  is



wherein  $\text{R}^9$  is halo or  $\text{NO}_2$  and  $\text{R}^{10}$  is halo; or


$\text{Ar}^2$  is




wherein  $\text{R}^9$  is halo or  $\text{NO}_2$ , and  $\text{R}^{10}$  is OMe, halo, OH,  $\text{NO}_2$ , phenyl,  $\text{C}(\text{O})\text{OH}$  or  $\text{C}(\text{O})\text{OMe}$ .

**Claim 22 (canceled)**


**Claim 23 (original):** A compound of formula 1, according to claim 17, wherein  $\text{Ar}^1$  is:



and wherein  $R^{12}$  selected from the group consisting of:




and



**Claim 24 (canceled)**

**Claim 25 (currently amended):** A compound of formula **1**, according to claim 17,  
 wherein

$Ar^2$  is selected from the group consisting of



wherein  $R^9$  is Cl or  $NO_2$  and


$R^{10A}$  is  $C_{1-4}$ alkyl;


$R^{10}$  is selected from the group consisting of  $(C_{1-4})$ alkyl,  $(C_{3-7})$ cycloalkyl,  $(C_{3-7})$ cycloalkyl- $(C_{1-3})$ alkyl,  $(C_{2-6})$ alkenyl,  $O(C_{1-6})$ alkyl,  $S(C_{1-6})$ alkyl, halo,  $CF_3$ ,  $OCF_3$ , OH,  $NO_2$ , CN,  $-NR^{N1}R^{N2}$ ,  $-C(O)R^{21}$ ,  $-(C_{1-3})$ alkyl- $C(O)R^{21}$ ,  $-C(O)OR^{22}$ ,  $-(C_{1-3})$ alkyl- $C(O)OR^{22}$ ,  $-SO_2-(C_{1-3})$ alkyl- $C(O)OR^{22}$ ,  $-(C_{1-3})$ alkyl- $C(O)NH_2$ ,  $C(O)NH_2$ ,  $-S(O)-(C_{1-6})$ alkyl,  $-SO_2-(C_{1-6})$ alkyl,  $-SO_2$ -phenyl,  $-SO_2-NH_2$ , phenyl, phenylmethyl, phenyl- $SO_2$ -, 2-, 3- or 4-pyridinyl, 1-pyrrolyl, whereby said phenyl, pyridinyl and pyrrolyl may have one or more substituents selected from the group consisting of halo,  $NO_2$ ,  $C_{1-3}$ -alkyl and  $CF_3$ ;

wherein  $R^{21}$  is  $(C_{1-4})$ alkyl and  $R^{22}$  is H or  $(C_{1-4})$ alkyl;

wherein  $R^{N1}$ ,  $R^{N2}$  each independently represent H or  $(C_{1-6})$ alkyl, whereby  $R^{N1}$  and  $R^{N2}$  may be covalently bonded to each other to form together with the N-atom to which they are attached to a 4 to 7-membered heterocycle whereby the  $-CH_2$ -group at the position 4 of a 6 or 7-membered heterocycle may be replaced by  $-O-$ ,  $-S-$  or  $-NR^{N3}-$  wherein  $R^{N3}$  represents H,  $-C(O)OR^{22}$ ,  $(C_{1-6})$ alkyl,  $(C_{3-7})$ cycloalkyl or  $(C_{3-7})$ cycloalkyl- $(C_{1-3})$ alkyl, wherein  $R^{22}$  is H or  $(C_{1-4})$ alkyl.

**Claim 26 (original):** A compound of formula 1, according to claim 25, wherein  $Ar^2$  is:





**Claim 27 (canceled)**

**Claim 28 (original):** A pharmaceutical composition comprising a compound of formula **1** as defined in claim 17, or a pharmaceutically acceptable salt thereof, and optionally one or more pharmaceutically acceptable carriers.

**Claim 29 (canceled)**

**Claim 30 (original):** A pharmaceutical composition for the treatment of HIV infection, comprising a compound of formula **1** as defined in claim 17, or a pharmaceutically acceptable salt thereof.

**Claim 31 (canceled)**